Mazdutide: A Two-Part Weight Loss Approach
Mazdutide is a peptide that works like a dual remote control for your metabolism. Researchers created it to help people lose weight and improve their metabolic health by activating two different biological pathways at the same time, rather than just one. It's still relatively new—it's finished early-stage testing in China and showed impressive results—but it represents a different strategy than some other popular weight loss peptides out there.
Here's how it actually works in your body. When you inject mazdutide, it activates two separate receptors: the GLP-1 receptor and the glucagon receptor. Think of these as two different switches on your body's control panel. The GLP-1 switch does what many people know—it reduces your appetite, slows down your digestion, and helps control blood sugar by signaling your pancreas to release insulin. But mazdutide adds a second switch: glucagon activation. This tells your liver and muscles to burn through stored fat faster and generate more heat, essentially revving up your metabolism like you just exercised. So you're losing weight two ways at once—you're eating less because you're not hungry, and simultaneously your body is burning more calories just sitting still. This dual approach also appears to help clean up excess fat in the liver, which is a bonus benefit beyond the weight loss itself.
Dosage Information
Typical Dose
3-9 mg weekly (Phase 2 trial doses)
Frequency
Once weekly
Administration
Subcutaneous injection
Half-Life
4–5 days
Notes
Phase 2 completed in China. International Phase 3 development ongoing. Not yet approved outside of China. Entry documents research context.
Why this matters
Dual GLP-1/glucagon agonist; once-weekly injection in clinical trials.
Protocol cycle
Dose Calculator
Calculate your draw amount for an insulin syringe (U-100)
Concentration: 2,500 mcg/mL
Sign in to save your reconstitution settings for this peptide
Draw to the
120
unit mark
Draw 120 units for your 3000mcg dose of Mazdutide
This calculator is for educational purposes. Always verify your calculations and consult a healthcare professional.
Where does Mazdutide sit?
See how this peptide compares across all 150 peptides in our database.
Evidence Score
0.71
Compound Data
Molecular Formula
C207H317N45O65
Molecular Weight
4476.00 g/mol
IUPAC Name
20-[[(1S)-4-[2-[2-[2-[2-[2-[2-[[(5S)-5-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-2-methylpropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]hexanoyl]amino]hexanoyl]amino]propanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[2-[(2S)-2-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-6-oxohexyl]amino]-2-oxoethoxy]ethoxy]ethylamino]-2-oxoethoxy]ethoxy]ethylamino]-1-carboxy-4-oxobutyl]amino]-20-oxoicosanoic acid
PubChem CID
167312357Potential Side Effects
Mazdutide discussions
Quick Facts
- Administration
- Subcutaneous injection
- Typical Dose
- 3-9 mg weekly (Phase 2 trial doses)
- Frequency
- Once weekly
- References
- 0 curated + 19 from PubMed
- Clinical Trials
- 20 registered
- Evidence Score
- 0.7 / 100
Frequently Asked Questions about Mazdutide
What is Mazdutide?
Mazdutide (IBI362) is a dual GLP-1 and glucagon receptor co-agonist developed by Innovent Biologics that has completed Phase 2 trials in China showing significant weight loss and metabolic improvements. It represents a different approach to dual receptor agonism from tirzepatide — combining GLP-1 with glucagon rather than GLP-1 with GIP. The glucagon component drives enhanced energy expenditure and fat oxidation complementing GLP-1's appetite suppression for a metabolically distinct profile.
How does Mazdutide work?
Mazdutide activates both GLP-1 receptors and glucagon receptors with balanced agonism. GLP-1 receptor activation provides the established benefits of incretin signaling — insulin secretion glucagon suppression gastric emptying delay and appetite reduction. Glucagon receptor activation adds direct hepatic effects including increased fat oxidation gluconeogenesis stimulation and thermogenesis. The glucagon component's thermogenic effects are particularly valuable — increasing basal metabolic rate means weight loss occurs through both caloric restriction and increased energy expenditure simultaneously. This dual mechanism has shown favorable effects on liver fat content making it particularly interesting for non-alcoholic fatty liver disease (NAFLD) applications beyond obesity.
What is the recommended dosage for Mazdutide?
The typical dose is 3-9 mg weekly (Phase 2 trial doses). Once weekly. Administration: Subcutaneous injection. Phase 2 completed in China. International Phase 3 development ongoing. Not yet approved outside of China. Entry documents research context.
What are the side effects of Mazdutide?
Nausea (common). Decreased appetite (common). Diarrhea (common). Vomiting (uncommon)
What is the Mazdutide cycle protocol?
Mazdutide is typically cycled ongoing. Once weekly subcutaneous injection, Phase 2/3 development
Questions reflect common community inquiries. This is not medical advice.